ACRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aclaris Therapeutics Inc (ACRS) does not present a strong buying opportunity for a beginner investor with a long-term strategy at this time. The stock's technical indicators, poor financial performance, and lack of positive catalysts suggest limited potential for immediate upside. While analysts have a Buy rating with a $10 price target, the company's recent financials and lack of significant trading trends do not support a strong buy decision.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 48.391, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support levels are at 3.305 and 3.131, with resistance at 3.871 and 4.045. However, the overall trend does not suggest a strong upward move in the near term.
Analyst coverage initiated with a Buy rating and a $10 price target, citing potential for ATI-052 and Phase 1b data readouts in the second half of 2026.
No recent news or significant trading trends. Financial performance is poor, with revenue, net income, and EPS showing significant YoY declines. Gross margin improvement is minimal and still negative. No recent congress trading data or influential figure activity.
In Q4 2025, revenue dropped by -85.94% YoY to $1,295,000. Net income fell by -79.50% YoY to -$19,795,000. EPS declined by -84.16% YoY to -0.16. Gross margin increased to -13.44%, but remains negative.
Craig-Hallum initiated coverage with a Buy rating and a $10 price target, citing proof-of-concept potential and undervaluation ahead of Phase 1b data in the second half of 2026.
